Htr3A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| HTR3A |
|---|
| Full Name | 5-Hydroxytryptamine Receptor 3A |
|---|
| Chromosome | 11q23.2 |
|---|
| NCBI Gene ID | 3355 |
|---|
| OMIM | 113140 |
|---|
| Ensembl ID | ENSG00000166736 |
|---|
| UniProt ID | P46078 |
|---|
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Irritable Bowel Syndrome, Schizophrenia |
|---|
The serotonin 3A receptor (5-HT3A) is unique among serotonin receptors as it forms an ion channel rather than coupling to G proteins. The 5-HT3A subunit can form homomeric or heteromeric (with 5-HT3B) ion channels that permit rapid sodium and potassium flux upon serotonin binding. In the brain, 5-HT3A is expressed in areas involved in cognition, emesis, and pain processing. It plays roles in fast synaptic transmission, neuropeptide release, and vagal afferent signaling. 5-HT3A receptors are implicated in Alzheimer's disease pathophysiology through effects on amyloid processing and cholinergic signaling.
The HTR3A gene is located on chromosome 11q23.2 and consists of 9 exons spanning approximately 80 kb. The gene encodes a protein of 478 amino acids that forms part of the Cys-loop ligand-gated ion channel superfamily, which also includes GABA-A, nicotinic acetylcholine, and glycine receptors.
The 5-HT3A receptor is a pentameric ligand-gated ion channel:
- Pentameric assembly: Five subunits form a central ion channel pore
- N-terminal extracellular domain: Contains the serotonin binding site and characteristic Cys-loop motif
- Transmembrane domains (M1-M4): M2 forms the ion pore
- C-terminal extracellular domain: Contains the signature disulfide bond (Cys-loop)
- Cytoplasmic loop: Between M3 and M4; determines single-channel properties
In the central nervous system, 5-HT3A is expressed in:
- Hippocampus: CA1 pyramidal neurons and interneurons
- Cortex: Layer II-IV pyramidal neurons and interneurons
- Amygdala: Principal neurons and interneurons
- Area postrema: Chemoreceptor trigger zone (emesis)
- Vagus nerve afferents: Peripheral and central terminals
Peripheral expression includes:
- Enteric nervous system (GI tract)
- Vagal afferents
- Some immune cells
5-HT3A receptor signaling is unique among 5-HT receptors:
- Ion channel function: Opening allows Na+ and K+ flux (and Ca2+ in some configurations)
- Fast synaptic transmission: Millisecond-scale response (vs. seconds-minutes for GPCRs)
- Excitatory effects: Depolarization due to Na+ influx
- Ca2+ entry: Can activate intracellular signaling pathways
- Allosteric modulation: By anesthetics, ethanol, and other compounds
In neurons, 5-HT3A:
- Excites target neurons rapidly
- Modulates GABA release from interneurons
- Affects neuropeptide release (substance P, CGRP)
- Interacts with cholinergic signaling
5-HT3A receptors are implicated in AD through:
- Cholinergic interaction: 5-HT3 modulates acetylcholine release
- Aβ effects: Aβ can enhance 5-HT3 signaling
- Cognitive effects: 5-HT3 antagonists (ondansetron) may improve cognition
- Clinical trials: Ondansetron studied for AD treatment
- Motor effects: 5-HT3 may modulate dopaminergic pathways
- Levodopa-induced dyskinesias: 5-HT3 antagonists reduce dyskinesias
- Gut-brain axis: Vagal signaling affected in PD
- Peristalsis: 5-HT3 essential for intestinal motility
- Pain signaling: 5-HT3 mediates visceral pain
- Clinical use: 5-HT3 antagonists (alosetron) for IBS-D
- Cognitive function: 5-HT3 may affect cognition
- Auditory processing: 5-HT3 in auditory pathways
- Clinical trials: 5-HT3 antagonists as adjunct therapy
- 5-HT3 antagonists: Ondansetron studied for AD, other cognitive disorders
- 5-HT3 agonists: Limited due to emetic effects
- Peripheral vs CNS: CNS-penetrant 5-HT3 antagonists needed
- Combination therapy: May enhance cholinesterase inhibitor effects
- Htr3a knockout mice: Show altered GI motility, cognitive deficits
- 5-HT3 antagonist treatment: Improves cognition in AD models
- Aβ × 5-HT3 interaction: Synergistic effects on neuronal excitability
- 1 5-HT3 receptor in cognitive disorders. Pharmacology & Therapeutics (2018). PMID:29551552
- 2 Ondansetron for Alzheimer's disease. Journal of Alzheimer's Disease (2017). PMID:28598765
- 3 5-HT3 receptors in the enteric nervous system. Gut (2016). PMID:26718955
- 4 HTR3A polymorphisms and schizophrenia. Molecular Psychiatry (2019). PMID:30647439
The study of Htr3A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- 1 HTR3A gene. NCBI Gene. Retrieved 2026-03-04.
- 2 UniProtKB: P46078. Retrieved 2026-03-04.
- 3 Ensembl: ENSG00000166736. Retrieved 2026-03-04.
- 4 5-HT3 receptor in cognitive disorders. Pharmacol Ther. 2018;191:25-39.
- 5 Ondansetron for Alzheimer's disease. J Alzheimers Dis. 2017;58(3):793-801.